Search Results

management of patients with rectal cancer. Discuss the role of adjuvant therapy in the management of rectal cancer. Patients with AJCC stage II (invasion through the muscularis layers) and III (node-positive) rectal cancer are at high risk for both

Panel Adds to Pancreatic Cancer Recommendations For the first time in decades, advances in diagnostics and adjuvant therapies appear to be improving outcomes in pancreatic cancer. These advances are reflected in additions to the NCCN Clinical

. The thoracoscopic approach is oncologically equivalent to thoracotomy, while resulting in fewer complications, improved quality of life, shorter length of stay, and superior compliance with adjuvant therapies. 6 – 8 Oncologic Outcomes The

, patients are categorized based on the predominant subtype. Although the prognostic value of subtyping relative to adjuvant therapy and neoadjuvant therapy remains unclear, Dr. Behrman underscored the importance of subtyping for future therapeutic

analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001 ; 19 : 3622 – 3634 . 2 Kirkwood JM Strawderman MH Ernstoff MS . Interferon alfa-2b adjuvant therapy of high

offer surgical treatment and more likely to use induction therapy before resection, whereas European surgeons preferred to offer OP followed by adjuvant therapy in select cases of N2 disease. Different therapeutic methods were compared in previous

patients with very low risk WT, as described in the text, who were candidates to receive no adjuvant therapy. The structure of the AREN ‘0’ studies is depicted in Figure 2 . An expanded menu of biologic and clinical prognostic factors, including

Center, and Vice Chair of the NCCN Guidelines Panel for Kidney Cancer, as he introduced his presentation at the NCCN 23rd Annual Conference. Adjuvant Therapy Five adjuvant therapy trials have been conducted in renal cell carcinoma (RCC). The ASSURE

different: for RTOG 9402, neoadjuvant therapy consisted of PCV chemotherapy before RT, and in EORTC 26951 adjuvant therapy consisted of PCV chemotherapy after RT. However, toxicity from the PCV regimen was an issue in both studies. “A lot of patients did not

pembrolizumab to maintenance olaparib, with arms stratified by mutation profile and exceptional response to platinum therapy. Adjuvant Therapy: Overall Survival Advantage Proven Based on the phase III PRODIGE 24/CCTG PA.6 trial, the state-of-the-art adjuvant